Price Alert

Milestone Pharmaceuticals... (MIST)

NASDAQ: MIST · Real-Time Price · USD

1.70

0.02 (1.19%)

At close: Aug 15, 2025, 1:06 PM

1.19% (1D)

Bid	1.69
Market Cap	144.07M
Revenue (ttm)	n/a
Net Income (ttm)	-31.16M
EPS (ttm)	-0.84
PE Ratio (ttm)	-2.02
Forward PE	-1.86
Analyst	Buy

Ask	1.73
Volume	462,903
Avg. Volume (20D)	1,404,077
Open	1.70
Previous Close	1.68
Day's Range	1.67 - 1.72
52-Week Range	0.63 - 2.75
Beta	0.52

About MIST

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MIST

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MIST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Milestone Pharmaceuticals Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-39.06%

Milestone Pharmaceuticals shares are trading lower... Unlock content with Pro Subscription

1 month ago

-39.06%

Milestone Pharmaceuticals shares are trading lower after the company announced a public offering.

News

4 weeks ago · seekingalpha.com

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Despite the CRL setback and heavy dilution, we remain optimistic on etripamil's long-term market potential and Milestone's investment thesis. The recent $52.5 million equity raise was poorly timed and...

1 month ago · benzinga.com

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index dipping more than 250 points on Friday.

1 month ago · seekingalpha.com

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

I rate Milestone Pharmaceuticals Inc. a Strong Buy under $2, expecting FDA approval for Cardamyst in early 2026 after addressing recent regulatory setbacks. Cardamyst offers a unique, self-administere...

2 months ago · zacks.com

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

Milestone Pharmaceuticals (MIST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).